2019-09-17 08:00
The authors depicture the biological drivers behind CDK4/6 resistance, succeeded by how DiviTumÒ can contribute to identifying patients where an early switch to an alternative treatment can improve patient outcome and support treatment decisions...
2019-08-28 07:55
Based on the feedback from the FDA, Biovica has now a clear path to a 510(k) submission and clearance for DiviTum. In the supplement II process, topics such as intended use, clinical validation plan and predicate device were discussed. This is the third...
2019-07-25 12:16
On the 22nd of July, Biovica had fruitful meeting with the FDA regarding Supplement II that discusses the approach for clinical validation of DiviTum. Next step is to document the conclusions from the meeting, which the FDA will review and signoff. This...
2019-05-22 09:45
DiviTum® has to date been investigated in seventeen clinical studies, of which eight were within the breast cancer area. In breast cancer, over 1,000 patients have participated, where the majority have been patients with metastatic breast cancer (n=845)...
2019-05-08 11:09
ASCO brings together more than 32,000 oncology professionals from across the globe to share the latest clinical cancer research impacting patient care. The Biovica team will attend the ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago...
2019-05-06 08:00
The study, which evaluated standard hormonal therapies in metastatic breast cancer, used the DiviTum® blood test as a non-invasive tool to monitor therapy efficacy. A total of 244 patients had their blood samples analyzed with DiviTum® and the...
2019-04-10 14:00
The agreement gives IBL-America non-exclusive rights to sell DiviTum® to pharmaceutical companies, Contract Research Organizations and research institutes in the US. The collaboration will further increase the commercial activities for this customer...
2019-04-09 22:30
The board of directors of Biovica has, based on the authorization given by the extraordinary general meeting, and as communicated in the Company’s press release earlier today, resolved to carry out a directed new share issue of 6,000,000 Class B...
2019-04-09 17:31
Biovica today announces its intention to carry out a directed new share issue of Class B shares of SEK 45-60 million, directed towards qualified investors in Sweden and internationally (the ”Directed New Share Issue”). Biovica has engaged...
2019-04-01 08:00
The patent is a kit-patent that protects against competing companies making copies of Biovicas product. The patent complements previous patent on the US market, which protects the method for the analyzis, making the protection even stronger. The patent...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects